Mycophenolate Mofetil

證據等級: L5

預測適應症: 10 個

Mycophenolate Mofetil: From Organ Transplant Rejection Prophylaxis to HIV Infectious Disease

One-Sentence Summary

Mycophenolate mofetil (MMF) is a purine-synthesis-inhibiting immunosuppressant historically used to prevent rejection after solid organ transplantation. The TxGNN model predicts it may be effective for HIV infectious disease, with 10 clinical trials and 20 publications currently retrieved in support of this direction — though the strongest human data date from small, mostly investigator-initiated studies conducted in the early-to-mid 2000s.

Quick Overview

Item	Content
Original Indication	Prophylaxis of organ transplant rejection (renal, cardiac, hepatic) — based on general pharmacological knowledge; no Finland-specific approved indication text is available (see below)
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.86%
Evidence Level	L2
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Structured mechanism-of-action data for this candidate were not returned from DrugBank (flagged as a High-severity data gap, DG002). However, the repurposing evidence pack supplies a specific mechanistic rationale: MMF inhibits inosine monophosphate dehydrogenase (IMPDH), depleting the guanine nucleotide pool and blocking proliferation of lymphocytes — including activated CD4+ T cells, the primary target/reservoir cells for HIV replication.

This is not a purely speculative mechanistic leap. Because activated, proliferating CD4+ T cells are both the preferred substrate for HIV infection and the cell population MMF most potently suppresses, researchers proposed in the late 1990s and 2000s that MMF could shrink the pool of cells available for viral replication and slow CD4+ T-cell depletion in chronic HIV-1 infection. MMF was also studied as an adjunct to nucleoside reverse transcriptase inhibitors (particularly abacavir and didanosine), where mycophenolic acid was shown to deplete intracellular deoxyguanosine triphosphate (dGTP) and potentiate antiretroviral activity in vitro and in small clinical cohorts.

Taken together, the prediction reflects a genuine, previously-tested immunomodulatory hypothesis rather than a novel mechanistic guess — but the human evidence base remains limited to small, mostly Phase 1/2 pilot and cohort studies, several of which were terminated or withdrawn before completion.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00120419	Phase 4	Unknown	90	MAN2 study — evaluates whether MMF can dampen chronic immune hyperactivation and slow CD4+ T-cell decline in ART-naive chronic HIV-1 patients, and its effect on HIV-1 RNA and disease progression
NCT00247494	Phase 4	Unknown	90	MAN2 substudy assessing effects of MMF on cardiovascular surrogate markers in HIV-1 infected patients
NCT00021489	Phase 1/2	Withdrawn	0	Planned safety/tolerability and antiretroviral-activity study of MMF added to abacavir in heavily treatment-experienced HIV patients; withdrawn before enrollment, no data generated
NCT00009009	Phase 2	Completed	10	Renal transplantation in HIV-infected patients with end-stage renal disease, examining safety of MMF-based immunosuppression in this population
NCT02793544	Phase 2	Completed	80	HLA-mismatched unrelated donor bone marrow transplant (HIV-cure-directed research context) using MMF as standard GVHD prophylaxis, not as the primary study drug
NCT00112593	N/A	Completed	5	Allogeneic HSCT to induce mixed hematopoietic chimerism in HIV-1-infected patients, with post-transplant immunosuppression using cyclosporine and MMF
NCT01453192	Phase 3	Completed	27	Multicenter follow-up of renal transplantation in HIV-1 infected patients with end-stage renal insufficiency, evaluating acute graft rejection incidence
NCT00038272	Phase 2	Completed	56	Pilot RCT of amdoxovir (DAPD) with or without MMF in treatment-experienced HIV patients; primary study drug is DAPD, MMF is an add-on arm
NCT01288131	Phase 3	Terminated	8	MMF plus cyclosporine vs. cyclophosphamide plus prednisolone for anti-EPO-associated pure red cell aplasia — not an HIV indication
NCT06869265	Phase 2	Recruiting	56	Thiotepa/busulfan/fludarabine conditioning for haploidentical HSCT in elderly AML patients — unrelated to MMF/HIV, likely a keyword co-occurrence mismatch

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15213566	2004	Randomized pilot study	J Acquir Immune Defic Syndr	17 chronic HIV-1 patients randomized to MMF vs. continued HAART after treatment interruption; assessed immune response and plasma/lymphatic tissue viral load
15353978	2004	Controlled trial	AIDS	HAART with or without MMF in treatment-naive HIV-1 patients; studied effect on plasma HIV-1 RNA decay rate and the latent reservoir
16379601	2005	Cohort (Tier 1)	AIDS Res Hum Retroviruses	No detrimental immunological effects observed when combining MMF with HAART in treatment-naive acute/chronic HIV-1 patients
12352149	2002	Cohort (Tier 1)	J Acquir Immune Defic Syndr	Adding MMF to abacavir-containing ART was associated with intracellular dGTP depletion and decreased plasma HIV-1 RNA in 5 heavily pretreated patients
41118390	2025	Cohort	J Clin Invest	Antiproliferative drugs combined with cognate peptide stimulation selectively reduced clonally expanded HIV-infected CD4+ T cells
15871638	2005	PK study	Clin Pharmacokinet	Pharmacokinetics/pharmacodynamics of low-dose MMF in HIV patients on abacavir, efavirenz, and nelfinavir
15355127	2004	PK study	Clin Pharmacokinet	Effect of MMF on pharmacokinetics of antiretrovirals and on intracellular nucleoside triphosphate pools
11391161	2001	Pilot study	J Acquir Immune Defic Syndr	Open-label pilot of MMF added to a multidrug-resistant HIV-1 regimen (abacavir, ddI, amprenavir, ritonavir ± efavirenz) in 7 heavily treated AIDS patients
17017956	2006	Review (Tier 2)	Curr Top Med Chem	Reviews immunosuppressive drugs, including MMF, as adjuncts to HAART targeting chronic immune activation in HIV disease
17885292	2007	Clinical study	AIDS	Safety, tolerability and antiretroviral activity of amdoxovir (DAPD) with or without MMF in drug-resistant HIV-1 infection

Finland Market Information

Mycophenolate mofetil is currently not marketed in Finland — no marketing authorizations are on record (0 licenses found). No product/dosage-form/indication data are available to tabulate.

Safety Considerations

Please refer to the package insert for safety information. Structured safety data (key warnings, contraindications, and drug–drug interaction records) could not be retrieved for this candidate; the TFDA-equivalent package insert warnings/contraindications are recorded as a Blocking data gap (DG001) that must be resolved before any S1 safety pre-assessment can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The IMPDH-inhibition mechanism gives a biologically coherent rationale for suppressing HIV target-cell proliferation, and this hypothesis was actually tested clinically in the 2000s (small cohorts, pilot RCTs, and one PK series) with encouraging but not definitive results — no confirmatory Phase 3 efficacy trial exists, several relevant studies were withdrawn or terminated, and the MAN2 study's outcome status remains "Unknown." Combined with the complete absence of validated safety/DDI data and the drug's non-marketed status in Finland, the evidence does not yet support proceeding to development or clinical guardrail design.

To proceed, the following is needed:

Official package insert / TFDA-equivalent warnings and contraindications (resolves Blocking gap DG001)
Confirmed mechanism-of-action documentation from DrugBank (resolves High-severity gap DG002)
A completed drug–drug interaction database query (currently "not_found")
Verification of final outcomes/publication status for the MAN2 study (NCT00120419/NCT00247494)
Assessment of the regulatory pathway required for Finland market entry if this indication is pursued further
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.